INTRODUÇÃO: O câncer de mama é o tipo mais incidente na população feminina mundial e brasileira, excetuando-se os casos de câncer de pele não melanoma, e também uma das principais causas de morte por câncer em países desenvolvidos e em desenvolvimento. As taxas de incidência são maiores nos ...
Fitzgerald, RC;
di, Pietro, M;
Ragunath, K;
Ang, Y;
Kang, JY;
Watson, P;
Trudgill, N;
Patel, P;
Kaye, PV;
Sanders, S;
O'Donovan, M;
Bird-Lieberman, E;
Bhandari, P;
Jankowski, JA;
Attwood, S;
Parsons, SL;
Loft, D;
Lagergren, J;
Moayyedi, P;
Lyratzopoulos, G;
de, Caestecker, J.
These guidelines provide a practical and evidence-based resource for the management of patients with Barrett's oesophagus and related early neoplasia. The Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument was followed to provide a methodological strategy for the guideline developm...
Ablation Techniques,
Adenocarcinoma/diagnosis,
Barrett Esophagus,
Biopsy,
Cost-Benefit Analysis,
Decision Support Techniques,
Early Detection of Cancer,
Esophageal Neoplasms,
Esophagectomy,
Esophagoscopy,
Esophagus,
Risk Assessment,
Risk Factors,
Barrett Esophagus/complications,
Barrett Esophagus/diagnosis,
Barrett Esophagus/economics,
Barrett Esophagus/therapy,
Esophageal Neoplasms/diagnosis,
Esophageal Neoplasms/therapy,
Adenocarcinoma/therapy
The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety ...
Cost-Benefit Analysis,
Tuberculosis, Multidrug-Resistant/drug therapy,
Drug Therapy, Combination,
Nitroimidazoles/therapeutic use,
Treatment Outcome,
Antitubercular Agents/therapeutic use,
Tuberculosis, Pulmonary/drug therapy,
Clinical Trials as Topic,
Nitroimidazoles/economics,
Antitubercular Agents/economics
This guideline covers the longer-term psychological treatment and management of self-harm in people aged 8 and over. It aims to improve the quality of care and support for people who self harm and covers both single and recurrent episodes of self-harm. This guideline follows on from self-harm in over 8s:...
